Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

作者: P Solal-Céligny , E Lepage , N Brousse , C L Tendler , P Brice

DOI: 10.1200/JCO.1998.16.7.2332

关键词: NeutropeniaFollicular lymphomaSurgeryInterferon alfaAlpha interferonGastroenterologyCyclophosphamideChemotherapyTeniposideInternal medicineMedicineRegimen

摘要: PURPOSETo compare progression-free survival (PFS), overall (OS), and toxicity of a doxorubicin-containing regimen administered alone or in combination with interferon alfa-2b (IFNalpha) patients low-grade follicular lymphoma (FL) poor prognostic factors.PATIENTS AND METHODSTwo hundred sixty-eight advanced-stage FL received cyclophosphamide, doxorubicin, teniposide, prednisone (CHVP) monthly for 6 months, then every 2 months 12 months. After randomization, 242 were evaluated efficacy: 119 CHVP alone, 123 also IFNalpha at dose 5 million units three times weekly 18 months.RESULTSAfter 6-year median follow-up, the treated + showed significantly longer PFS than those who (2.9 years v 1.5 years, respectively; P = .0002) OS (not reached 5.6 .008). Although some side effects, which included neutropenia, asthenia, ...

参考文章(11)
J E Romaguera, P McLaughlin, L North, D Dixon, K B Silvermintz, L A Garnsey, W S Velasquez, F B Hagemeister, F Cabanillas, Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. Journal of Clinical Oncology. ,vol. 9, pp. 762- 769 ,(1991) , 10.1200/JCO.1991.9.5.762
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
J. U. Gutterman, Cytokine therapeutics: lessons from interferon alpha. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 1198- 1205 ,(1994) , 10.1073/PNAS.91.4.1198
Philippe Solal-Celigny, Eric Lepage, Nicole Brousse, Felix Reyes, Corinne Haioun, Michel Leporrier, Michel Peuchmaur, Andre Bosly, Yolaine Parlier, Pauline Brice, Bertrand Coiffier, Christian Gisselbrecht, Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma New England Journal of Medicine. ,vol. 329, pp. 1608- 1614 ,(1993) , 10.1056/NEJM199311253292203
P Brice, Y Bastion, E Lepage, N Brousse, C Haïoun, P Moreau, N Straetmans, H Tilly, I Tabah, P Solal-Céligny, Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte Journal of Clinical Oncology. ,vol. 15, pp. 1110- 1117 ,(1997) , 10.1200/JCO.1997.15.3.1110
A Hagenbeek, P Carde, J H Meerwaldt, R Somers, J Thomas, R De Bock, J M Raemaekers, A van Hoof, C De Wolf-Peeters, M van Glabbeke, Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology. ,vol. 16, pp. 41- 47 ,(1998) , 10.1200/JCO.1998.16.1.41
C J Gallagher, W M Gregory, A E Jones, A G Stansfeld, M A Richards, H S Dhaliwal, J S Malpas, T A Lister, Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology. ,vol. 4, pp. 1470- 1480 ,(1986) , 10.1200/JCO.1986.4.10.1470
E Lepage, C Gisselbrecht, F Reyes, C Sebban, D Sugano, C Tendler, A Goldhirsch, B F Cole, P Solal-Céligny, R D Gelber, Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. Journal of Clinical Oncology. ,vol. 16, pp. 2339- 2344 ,(1998) , 10.1200/JCO.1998.16.7.2339
Janet W. Andersen, Richard V. Smalley, Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up. The New England Journal of Medicine. ,vol. 329, pp. 1821- 1822 ,(1993) , 10.1056/NEJM199312093292419